EUVIMEDEUVIMED entdecken
Crossref

Impact of statin use in head and neck cancer: a nested case–control study

Haewon Rhi, Hyo Geun Choi, Jeong Wook Kang

European Archives of Oto-Rhino-Laryngology · 2025

DOI: 10.1007/s00405-024-09020-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Haewon Rhi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University Sacred Heart Hospital, Anyang, 14068, Republic of Korea. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Hallym University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Dyslipidemia and statin use are associated with an increased risk of various cancers. However, the association in head and neck cancer (HNC) remains unclear. Therefore, this study aimed to investigate the impact of dyslipidemia and statin use on the development of HNC. METHODS: Using data from the Korean National Health Insurance Service-National Sample Cohort from 2002 to 2019, we compared two groups HNC patients (n = 1006) and matched control participants (n = 4024) after propensity score overlap weighted balancing. The odds ratios (ORs) for HNC development according to dyslipidemia and statin use duration were assessed using propensity score overlap-weighted multivariable logistic regression. RESULTS: Individuals with untreated dyslipidemia had significantly lower odds of developing HNC than those of normal participants (OR 0.70, 95% confidence interval [CI] 0.59-0.82). Conversely, patients with dyslipidemia who received statin therapy (< 60 days) showed a nearly two-fold increase in the odds of HNC (OR 1.94, 95% CI 1.29-2.90). Long-term statin use (≥ 60 days) aligned the odds with those of normal participants (OR 0.89, 95% CI 0.76-1.04). CONCLUSIONS: The adverse effect of short-term statin use on HNC development requires further study, and long-term statin use for dyslipidemia treatment does not increase the odds of HNC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasHumansMaleFemaleMiddle AgedCase-Control StudiesAgedRepublic of KoreaPropensity ScoreAdultRisk Factors

Stichwörter der Autor:innen

CancerDyslipidemiaHead and neck cancerHyperlipidemiaStatin

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University Sacred Heart Hospital, Anyang, 14068, Republic of Korea.
  • Suseo Seoul ENT Clinic and MD Analytics, 10, Bamgogae-ro 1-gil, Gangnam-gu, Seoul, 06349, Republic of Korea.
  • Department of Otorhinolaryngology-Head & Neck Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, #22, Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang, 14068, Republic of Korea. simbody…

Förderung

  • Hallym University Research Fund

Zitieren

APA

Rhi, H., Choi, H. G., & Kang, J. W. (2025). Impact of statin use in head and neck cancer: a nested case–control study. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-09020-1

Vancouver

Rhi H, Choi HG, Kang JW. Impact of statin use in head and neck cancer: a nested case–control study. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-024-09020-1

BibTeX
@article{Rhi2025,
  author = {Rhi, Haewon and Choi, Hyo Geun and Kang, Jeong Wook},
  title = {Impact of statin use in head and neck cancer: a nested case–control study},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2025},
  doi = {10.1007/s00405-024-09020-1}
}
Kostenlos starten →